This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
73
S-1 40-60 mg bid day 1~day 7 LV 25 mg bid day 1~day 7
Sun Yat-sen University Cancer Center, Division of Oncology
Dong Feng Dong road,Guangzhou, Guangdong, China
Shanghai Fudan University Cancer Hospital, Division of Oncology
Dong An Road, Shanghai, China
PLA 307 Hospital, No.4 Division of Oncology
East Avenue, Fengtai District, Beijing, China
Overall Response Rate (ORR)
Time frame: During chemotherapy
Safety
Time frame: During chemotherapy
Progression free survival (PFS)
Time frame: Until progression
Disease control rate(DCR)
Time frame: During chemotherapy
Time to treatment failure (TTF)
Time frame: Until progression
Overall survival (OS)
Time frame: Over two years from registration
Feasibility
Time frame: During chemotherapy
Pharmacokinetics
Time frame: During chemotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Beijing Cancer Hospital, Digestive System Medicine Department
Fucheng Road, Haidian District, Beijing, China
Cancer Institute & Hospital Chinese Academy of Medical Sciences, Division of Oncology
Panjiayuan Nanli, Chaoyang District, Beijing, China
Graduate School of Medical Sciences Kumamoto University
1-1-1, Honjo Kumamoto-city, Kumamoto, Japan